|

One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS

RECRUITINGSponsored by Fondazione IRCCS Policlinico San Matteo di Pavia
Actively Recruiting
SponsorFondazione IRCCS Policlinico San Matteo di Pavia
Started2025-11-28
Est. completion2026-06-30
Eligibility
Age18 Years – 99 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07448935

Summary

By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.

Eligibility

Age: 18 Years – 99 YearsHealthy volunteers accepted
Inclusion Criteria:

* Biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma
* Planned peripheral blood sampling +/- bone marrow aspiration
* Age \> 18 years
* Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written informed consent.

Exclusion Criteria:

* Undefined monoclonal gammopathy or non-AL amyloidosis
* Patients fulfilling the criteria for complete hematologic response after anti-clonal therapy
* Age \<18 years
* Failure to show willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes.

Conditions4

AL AmyloidosisCancerMultiple MyelomaPOEMS Syndrome

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.